Activated liver dendritic cells generate strong acquired immunity in α-galactosylceramide treatment
A Sasakawa, T Tatsumi, T Takehara, S Yamaguchi… - Journal of …, 2009 - Elsevier
BACKGROUND/AIMS: α-Galactosylceramide (α-GalCer) presented by dendritic cells (DCs)
activates NKT cells that in turn drive DC maturation. However, the potential of generating
acquired immunity of liver DCs in α-GalCer treatment remains unclear. METHODS: We
examined the activation of acquired immunity in the α-GalCer treatment against liver or
spleen tumor and the ability of liver and spleen DCs in the generation of acquired immunity.
RESULTS: Administration of α-GalCer resulted in generation of p53 peptide-specific …
activates NKT cells that in turn drive DC maturation. However, the potential of generating
acquired immunity of liver DCs in α-GalCer treatment remains unclear. METHODS: We
examined the activation of acquired immunity in the α-GalCer treatment against liver or
spleen tumor and the ability of liver and spleen DCs in the generation of acquired immunity.
RESULTS: Administration of α-GalCer resulted in generation of p53 peptide-specific …